BioMimetic trial results in

BioMimetic Therapeutics Inc. announced yesterday impressive data from randomized trials of its Augment Bone Graft product, showing it performed well in comparison with material harvested via autograft. The release is here. At 4:20 p.m. CT today, the stock was up about 20 percent over day-earlier.